Skip to main content
SpringerLink
Log in
Book cover

Management of Soft Tissue Sarcoma pp 93–111Cite as

Liposarcoma

  • Chapter
  • First Online:

  • 2562 Accesses

Abstract

Liposarcoma is primarily a tumor that occurs (Fig. 5.1) with peak incidence between ages 50 and 70 and equal gender distribution. As described previously (see Chap. 1, Fig. 1.6), liposarcomas account for approximately 20 % of all soft tissue sarcomas in adults. Anatomic distribution of liposarcoma is wide (Fig. 5.2) and is usually considered to manifest in three biological subtypes. The most common type is well-differentiated liposarcoma (sometimes called atypical lipomatous tumor [ALT]) and its high-grade variant dedifferentiated liposarcoma. The second most common is myxoid (low-grade) and round cell (high-grade) liposarcoma. The least common is (high-grade) pleomorphic liposarcoma. Each subtype has a very distinctive morphology, natural history, and genetic changes utilized in diagnosis.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   139.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   179.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Kooby DA, Antonescu CR, Brennan MF, et al. Atypical lipomatous tumor/well-differentiated liposarcoma of the extremity and trunk wall: importance of histological subtype with treatment recommendations. Ann Surg Oncol. 2004;11(1):78–84.

    Article  PubMed  Google Scholar 

  2. Russo P, Brady MS, Conlon K, et al. Adult urological sarcoma. J Urol. 1992;147(4):1032–6. discussion 1036–7.

    PubMed  CAS  Google Scholar 

  3. Shibata D, Lewis JJ, Leung DH, et al. Is there a role for incomplete resection in the management of retroperitoneal liposarcomas? J Am Coll Surg. 2001;193(4):373–9.

    Article  PubMed  CAS  Google Scholar 

  4. Alektiar KM, Hu K, Anderson L, et al. High-dose-rate intraoperative radiation therapy (HDR-IORT) for retroperitoneal sarcomas. Int J Radiat Oncol Biol Phys. 2000;47(1):157–63.

    Article  PubMed  CAS  Google Scholar 

  5. Al Yami A, Griffin AM, Ferguson PC, et al. Positive surgical margins in soft tissue sarcoma treated with preoperative radiation: is a postoperative boost necessary? Int J Radiat Oncol Biol Phys. 2010;77(4):1191–7.

    Article  PubMed  Google Scholar 

  6. Chung PW, Deheshi BM, Ferguson PC, et al. Radiosensitivity translates into excellent local control in extremity myxoid liposarcoma: a comparison with other soft tissue sarcomas. Cancer. 2009;115(14):3254–61.

    Article  PubMed  Google Scholar 

  7. Schwab JH, Boland PJ, Antonescu C, et al. Spinal metastases from myxoid liposarcoma warrant screening with magnetic resonance imaging. Cancer. 2007;110(8):1815–22.

    Article  PubMed  Google Scholar 

  8. Schwab JH, Boland P, Guo T, et al. Skeletal metastases in myxoid liposarcoma: an unusual pattern of distant spread. Ann Surg Oncol. 2007;14(4):1507–14.

    Article  PubMed  Google Scholar 

  9. Verweij J, Baker LH. Future treatment of soft tissue sarcomas will be driven by histological subtype and molecular aberrations. Eur J Cancer. 2010;46(5):863–8.

    Article  PubMed  CAS  Google Scholar 

  10. Romeo S, Dei Tos AP. Soft tissue tumors associated with EWSR1 translocation. Virchows Arch. 2010;456(2):219–34.

    Article  PubMed  CAS  Google Scholar 

  11. Rieker RJ, Weitz J, Lehner B, et al. Genomic profiling reveals subsets of dedifferentiated liposarcoma to follow separate molecular pathways. Virchows Arch. 2010;456(3):277–85.

    Article  PubMed  CAS  Google Scholar 

  12. Guillou L, Aurias A. Soft tissue sarcomas with complex genomic profiles. Virchows Arch. 2010;456(2):201–17.

    Article  PubMed  CAS  Google Scholar 

  13. Pires de Camargo V, Van de Rijn M, Maestro R, et al. Other targetable sarcomas. Semin Oncol. 2009;36(4):358–71.

    Article  Google Scholar 

  14. Goransson M, Andersson MK, Forni C, et al. The myxoid liposarcoma FUS-DDIT3 fusion oncoprotein deregulates NF-kappaB target genes by interaction with NFKBIZ. Oncogene. 2009;28(2):270–8.

    Article  PubMed  CAS  Google Scholar 

  15. Italiano A, Bianchini L, Keslair F, et al. HMGA2 is the partner of MDM2 in well-differentiated and dedifferentiated liposarcomas whereas CDK4 belongs to a distinct inconsistent amplicon. Int J Cancer. 2008;122(10):2233–41.

    Article  PubMed  CAS  Google Scholar 

  16. Italiano A, Cardot N, Dupre F, et al. Gains and complex rearrangements of the 12q13-15 chromosomal region in ordinary lipomas: the “missing link” between lipomas and liposarcomas? Int J Cancer. 2007;121(2):308–15.

    Article  PubMed  CAS  Google Scholar 

  17. Antonescu CR. The role of genetic testing in soft tissue sarcoma. Histopathology. 2006;48(1):13–21.

    Article  PubMed  CAS  Google Scholar 

  18. Dei Tos AP. Liposarcoma: new entities and evolving concepts. Ann Diagn Pathol. 2000;4(4):252–66.

    Article  PubMed  CAS  Google Scholar 

  19. Mertens F, Fletcher CD, Dal Cin P, et al. Cytogenetic analysis of 46 pleomorphic soft tissue sarcomas and correlation with morphologic and clinical features: a report of the CHAMP Study Group. Chromosomes and MorPhology. Genes Chromosomes Cancer. 1998;22(1):16–25.

    Article  PubMed  CAS  Google Scholar 

  20. Turc-Carel C, Limon J, Dal Cin P, et al. Cytogenetic studies of adipose tissue tumors. II. Recurrent reciprocal translocation t(12;16)(q13;p11) in myxoid liposarcomas. Cancer Genet Cytogenet. 1986;23(4):291–9.

    Article  PubMed  CAS  Google Scholar 

  21. Jones RL, Fisher C, Al-Muderis O, et al. Differential sensitivity of liposarcoma subtypes to chemotherapy. Eur J Cancer. 2005;41(18):2853–60.

    Article  PubMed  CAS  Google Scholar 

  22. Eilber FC, Eilber FR, Eckardt J, et al. The impact of chemotherapy on the survival of patients with high-grade primary extremity liposarcoma. Ann Surg. 2004;240(4):686–95.

    PubMed  Google Scholar 

  23. Patel SR, Burgess MA, Plager C, et al. Myxoid liposarcoma. Experience with chemotherapy. Cancer. 1994;74(4):1265–9.

    Article  PubMed  CAS  Google Scholar 

  24. Pisters PW, O’Sullivan B, Maki RG. Evidence-based recommendations for local therapy for soft tissue sarcomas. J Clin Oncol. 2007;25(8):1003–8.

    Article  PubMed  Google Scholar 

  25. Pervaiz N, Colterjohn N, Farrokhyar F, et al. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer. 2008;113(3):573–81.

    Article  PubMed  Google Scholar 

  26. Grosso F, Sanfilippo R, Virdis E, et al. Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series. Ann Oncol. 2009;20(8):1439–44.

    Article  PubMed  CAS  Google Scholar 

  27. Demetri GD, Chawla SP, von Mehren M, et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol. 2009;27(25):4188–96.

    Article  PubMed  CAS  Google Scholar 

  28. Maki RG, Wathen JK, Patel SR, et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. J Clin Oncol. 2007;25(19):2755–63.

    Article  PubMed  CAS  Google Scholar 

  29. Chawla SP, Tolcher AW, Sankhala KK, et al. Updated interim results of a phase 2 study of the mTOR inhibitor AP23573 in patients with advanced sarcomas of soft tissue or bone. In: Connective Tissue Oncology Society 15th Annual Meeting, Vol. 15. Boca Raton; 2005. Abstract 447.

    Google Scholar 

  30. Chugh R, Wathen JK, Maki RG, et al. Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model. J Clin Oncol. 2009;27(19):3148–53.

    Article  PubMed  CAS  Google Scholar 

  31. Maki RG, D’Adamo DR, Keohan ML, et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol. 2009;27(19):3133–40.

    Article  PubMed  CAS  Google Scholar 

  32. Sleijfer S, Ray-Coquard I, Papai Z, et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol. 2009;27(19):3126–32.

    Article  PubMed  CAS  Google Scholar 

  33. Dalal KM, Kattan MW, Antonescu CR, et al. Subtype specific prognostic nomogram for patients with primary liposarcoma of the retroperitoneum, extremity, or trunk. Ann Surg. 2006;244(3):381–91.

    PubMed  Google Scholar 

  34. Grosso F, Jones RL, Demetri GD, et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol. 2007;8(7):595–602.

    Article  PubMed  CAS  Google Scholar 

  35. Muller CR, Paulsen EB, Noordhuis P, et al. Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A. Int J Cancer. 2007;121(1):199–205.

    Article  PubMed  CAS  Google Scholar 

  36. Singer S, Socci ND, Ambrosini G, et al. Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma. Cancer Res. 2007;67(14):6626–36.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. International Center & Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

    Murray F. Brennan

  2. Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

    Cristina R. Antonescu

  3. Departments of Medicine Pediatrics, and Orthopaedics, Mount Sinai School of Medicine, New York, NY, USA

    Robert G. Maki

Authors
  1. Murray F. Brennan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cristina R. Antonescu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Robert G. Maki
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

Brennan, M.F., Antonescu, C.R., Maki, R.G. (2013). Liposarcoma. In: Management of Soft Tissue Sarcoma. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-5004-7_5

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-5004-7_5

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-5003-0

  • Online ISBN: 978-1-4614-5004-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation